VRCA · Verrica Pharmaceuticals
AI read · Good for VRCA
The AI's read
Growing YCANTH sales and the added cash give Verrica more time to build its business and test other treatments. Its common-wart study is still underway, with first trial results expected in mid-2027, so those results are not yet known. The sales growth and funding support a positive read despite that wait.